ArticleHuman cell2009
Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer.
Article in Human cell, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 14 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 14 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- A systematic review on active sites and functions of PIM-1 protein.Human cell · 2022Pooled it
- Associations of MDM2 rs2279744 and TP53 rs1042522 polymorphisms with cervical cancer risk: A meta-analysis and systematic review.Frontiers in oncology · 2022Pooled it
- Association between genetic polymorphisms and endometrial cancer risk: a systematic review.Journal of medical genetics · 2020Pooled it
- Association between MDM2 SNP309 and endometrial cancer risk: A PRISMA-compliant meta-analysis.Medicine · 2018Pooled it
- Pooled it
- Relationship Between Murine Double Minute 2 (MDM2) T309G Polymorphism and Endometrial Cancer Risk: A Meta-Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2016Pooled it
- Evaluation of the p53 Arg72Pro polymorphism and its association with cancer risk: a HuGE review and meta-analysis.Genetics research · 2015Pooled it
- Common variant on MDM2 contributes to endometrial cancer susceptibility: evidence based on 7 studies.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- MDM2 rs2279744 polymorphism and endometrial cancer: a meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- MDM2 SNP309 polymorphism contributes to endometrial cancer susceptibility: evidence from a meta-analysis.Journal of experimental & clinical cancer research : CR · 2013Pooled it
- TP53 Arg72Pro polymorphism and endometrial cancer risk: a meta-analysis.Medical oncology (Northwood, London, England) · 2011Pooled it
- MDM2 309 T/G polymorphism is associated with colorectal cancer risk especially in Asians: a meta-analysis.Medical oncology (Northwood, London, England) · 2011Pooled it
- Pooled it
- MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis.BMC cancer · 2011Pooled it
- CP‑31398 attenuates endometrial cancer cell invasion, metastasis and resistance to apoptosis by downregulating MDM2 expression.International journal of oncology · 2019Article
- Lack of an Association between a Functional Polymorphism in theReports of biochemistry & molecular biology · 2017Article
- TP53 and MDM2 polymorphisms and the risk of endometrial cancer in postmenopausal women.Medical oncology (Northwood, London, England) · 2014Article
- Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer.Oncology reports · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetic polymorphisms of p53 and its negative regulator murine double minute 2 homolog (MDM2) have been shown to be closely associated with tumorigenesis in a variety of human cancers. In the present study, single nucleotide polymorphism (SNP) at p53 codon 72 and MDM2 promoter 309 was examined for germline DNA samples from 102 endometrial cancer cases and 95 controls using polymerase chain reaction-based fragment analysis. There were no significant differences in the genotype and allele prevalence between control subjects and endometrial cancer patients for p53 codon 72. The GG genotype frequency of MDM2-SNP309 was statistically higher in endometrial cancer patients than that in normal healthy women when compared with the TG genotype (P= 0.0088). However, no statistically significant differences were found between the TT and TG or GG genotype frequencies and allele prevalence. Interestingly, the combination of the homozygous Arg/Arg genotype of p53 codon 72 and homozygous GG genotype of MDM2 SNP309 polymorphisms was significantly associated with the risk of endometrial cancer (odds ratio = 3.28, 95% confidence interval = 1.13 to 9.53, P= 0.0212). The homozygous variants of wild p53 codon 72 and mutant MDM2 promoter 309 may cooperatively increase the risk of endometrial cancer in a Japanese population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.